Search

Your search keyword '"Palitti, V"' showing total 130 results

Search Constraints

Start Over You searched for: Author "Palitti, V" Remove constraint Author: "Palitti, V"
130 results on '"Palitti, V"'

Search Results

1. OC.05.7: CHOLESTASIS IMPACTS ON PERFORMANCE OF NON INVASIVE TESTS FOR RULING OUT HIGH-RISK ESOPHAGEALVARICES IN PATIENTS WITH PRIMARY BILIARY CHOLANGITIS AND COMPENSATED ADVANCED CHRONIC LIVER DISEASE

2. Longer transplant-free and liver-related event-free survival in obeticholic acid-treated patients with primary biliary cholangitis compared to external controls from two large real-world cohorts

3. Predictors of serious adverse events and non-response in cirrhotic patients with primary biliary cholangitis treated with obeticholic acid

4. Long-term results from the Italian real-world experience on obeticholic acid treatment in primary biliary cholangitis: The RECAPITULATE study

5. Prediction of response to obeticholic acid in primary biliary cholangitis: Development and validation of the OCA response score (ORS)

6. Resistance analysis and treatment outcomes in hepatitis C virus genotype 3-infected patients within the Italian network VIRONET-C

7. Real-world experience with obeticholic acid in patients with primary biliary cholangitis

8. Resistance analysis and treatment outcomes in hepatitis C virus genotype 3-infected patients within the Italian network VIRONET-C

9. Predictors of Serious Adverse Event and Non-response in Cirrhotic Patients With Primary Biliary Cholangitis under Obeticholic Acid

10. HCV NS3 sequencing as a reliable and clinically useful tool for the assessment of genotype and resistance mutations for clinical samples with different HCV-RNA levels

11. Efficacy and safety of lusutrombopag in a real-world Italian series of cirrhotic patients with severe thrombocytopenia undergoing invasive procedures: the Reality study

12. Prevalence and Characterization of Resistance Profiles of “Unusual” HCV Subtypes in Italy within the Italian Resistance Network Vironet C

13. Cholestasis impacts on performance of non invasive tests for ruling out high-risk esophageal varices in patients with primary biliary cholangitis and compensated advanced chronic liver disease

14. Biochemical response to obeticholic acid drives liver stiffness variation over time and the risk of liver-related events in patients with primary biliary cholangitis

16. Prevalence of Single and Multiple Natural NS3, NS5A and NS5B Resistance-Associated Substitutions in Hepatitis C Virus Genotypes 1-4 in Italy

17. Frequent NS5A and multiclass resistance in almost all HCV genotypes at DAA failures: What are the chances for second-line regimens?

20. DECLINE OF PREVALENCE OF RESISTANCE ASSOCIATED SUBSTITUTIONS TO NS3 AND NS5A INHIBITORS AT DAA- FAILURE IN HEPATITIS C VIRUS IN ITALY OVER THE YEARS 2015 TO 2018

21. Analysis of resistance and phylogenetic clusters in HCV-2c infected patients within the Italian network Vironet C

22. VIRONET-C real life experience of resistance-guided retreatment in HCV infected patients who previously failed a NS5A inhibitor-containing regimen

23. Real-world data on the treatment of primary biliary cholangitis with obeticholic acid in Italy: the CLEO-AIGO OCA cohort

24. HCV NS3 sequencing as a reliable and clinically useful tool for the assessment of genotype and resistance mutations for clinical samples with different HCV-RNA levels

25. Resistance test guided retreatment of HCV infected patients with a previous failure to a NS5A inhibitor-containing regimen: the Italian Vironet C real life experience

26. Characterization of baseline factors associated with treatment outcome in HCV-infected patients naive to direct acting antivirals: particular focus on natural resistance

28. Characterization of resistance profiles in HCV 2-3-4 DAA-naïve and DAA-experienced infected patients in Italy

29. Multiclass HCV resistance to direct-acting antiviral failure in real-life patients advocates for tailored second-line therapies

30. Natural HCV resistance is common in Italy and differently associated to genotypes

31. Prevalence and characteristics of resistance associated substitutions in DAA-naive and DAA-failed HCV-3 patients in Italy

32. Multiclass HCV resistance to interferon-free direct acting antivirals regimens in real life failures advocates for tailored second-line therapies

33. Daclatasvir/sofosbuvir and ribavirin 800mg flat dose is highly efficacy and safe in genotype 3 compensated and decompensated cirrhotic patients: The CLEO experience

34. Impact of different Sofosbuvir-based direct acting antiviral (DAA) regimen in elderly cirrhotic patients: A real world experience from CLEO Group

35. Daclatasvir/sofosbuvir and ribavirin 800 mg flat dose is highly efficacy and safe in genotype 3 compensated and decompensated cirrhotic patients: The CLEO experience

36. [Assessment of clinical competence of medical school graduates in Italy with standardized patients. The opinion of the examinees]

43. Impact of different scoring methods on the clinical skills assessment of internal medicine students.

44. Declino delle Sostituzioni associate a resistenza (RAS) ad inibitori di NS3 ed NS5A al fallimento con DAA nel virus dell’epatite C in Italia negli anni 2015-2018

47. Multiclass HCV resistance to direct-acting antiviral failure in real-life patients advocates for tailored second-line therapies

48. Real-world experience with obeticholic acid in patients with primary biliary cholangitis

49. Rate of non-response to ursodeoxycholic acid in a large real-world cohort of primary biliary cholangitis patients in Italy

50. Frequent NS5A and multiclass resistance in almost all HCV genotypes at DAA failures: What are the chances for second-line regimens?

Catalog

Books, media, physical & digital resources